<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="./datadict_v2.xsl"?><data_table id="pht002630.v1" study_id="phs000467.v1" participant_set="1" date_created="Tue Apr 10 15:17:42 2012"><variable id="phv00167618.v1"><name>SUBJID</name><description>TARGET Subject id</description><type>string</type></variable><variable id="phv00167619.v1"><name>AGE</name><description>Age at diagnosis</description><type>integer</type><unit>Days</unit><logical_min>5</logical_min><logical_max>7446</logical_max></variable><variable id="phv00167620.v1"><name>GENDER</name><description>Gender</description><type>string</type><value>Male</value><value>Female</value></variable><variable id="phv00167621.v1"><name>NAACCR_ETHNICITY</name><description>NAACCR Ethnicity</description><type>encoded value</type><logical_min>0</logical_min><logical_max>9</logical_max><value code="0">Non-Spanish, non-Hispanic</value><value code="1">Mexican (incl Chicano)</value><value code="2">Puerto Rican</value><value code="3">Cuban</value><value code="4">South or Central American (except Brazil)</value><value code="5">Other specified Spanish/Hispanic origin (includes European)</value><value code="6">Spanish NOS, Hispanic NOS, Latino NOS (based on more than just surname)</value><value code="7">Spanish surname only-no contrary evidence that the pt is not Hispanic</value><value code="9">Unknown whether Spanish only</value></variable><variable id="phv00167622.v1"><name>NAACCR_RACE</name><description>NAACCR Race</description><type>encoded value</type><logical_min>1</logical_min><logical_max>99</logical_max><value code="1">White</value><value code="2">Black</value><value code="3">American Indian, Aleutian, Eskimo</value><value code="4">Chinese</value><value code="5">Japanese</value><value code="6">Filipino</value><value code="7">Hawaiian</value><value code="8">Korean</value><value code="9">Asian Indian, Pakistani</value><value code="10">Vietnamese</value><value code="11">Laotian</value><value code="12">Hmong</value><value code="13">Kampuchean</value><value code="14">Thai</value><value code="20">Micronesian NOS</value><value code="21">Chamorran</value><value code="22">Guamanian, NOS</value><value code="25">Polynesian, NOS</value><value code="26">Tahitian</value><value code="27">Samoan</value><value code="28">Tongan</value><value code="30">Melanesian, NOS</value><value code="31">Fiji Islander</value><value code="32">New Guinean</value><value code="96">Other Asian, incl Asian NOS and Oriental NOS</value><value code="97">Pacific Islander, NOS</value><value code="98">Other</value><value code="99">Unknown</value></variable><variable id="phv00167623.v1"><name>inss_stage</name><description>INSS stage</description><type>encoded value</type><logical_min>1</logical_min><logical_max>9</logical_max><value code="1">Stage 1</value><value code="2">Stage 2a</value><value code="3">Stage 2b</value><value code="4">Stage 3</value><value code="5">Stage 4</value><value code="6">Stage 4s</value><value code="9">Unknown</value></variable><variable id="phv00167624.v1"><name>mycn</name><description>MYCN status</description><type>encoded value</type><logical_min>0</logical_min><logical_max>9</logical_max><value code="0">Not amplified</value><value code="1">Amplified</value><value code="9">Unknown, not done, unsatisfactory, in progress</value></variable><variable id="phv00167625.v1"><name>ploidy</name><description>Ploidy</description><type>encoded value</type><logical_min>0</logical_min><logical_max>9</logical_max><value code="0">DI &gt; 1 (hyperdiploid)</value><value code="1">DI &lt;= 1 (hypodiploid, diploid)</value><value code="9">Unknown</value></variable><variable id="phv00167626.v1"><name>hist</name><description>Revised INPC prognostic group (Cancer 2003). If INPC is missing, this is the Shimada classification (JNCI 1984).</description><type>encoded value</type><logical_min>0</logical_min><logical_max>9</logical_max><value code="0">Favorable</value><value code="1">Unfavorable</value><value code="9">Unknown, slides not received, inadequate</value></variable><variable id="phv00167627.v1"><name>grade</name><description>Grade of Neuroblastic Differentiation (Revised INPC).  If INPC grade is missing, then this is Shimada grade.</description><type>encoded value</type><logical_min>0</logical_min><logical_max>9</logical_max><value code="0">Undifferentiated or Poorly Differentiated</value><value code="1">Differentiating</value><value code="9">Unknown</value></variable><variable id="phv00167628.v1"><name>mki</name><description>MKI (Revised INPC).  If INPC MKI is missing, then this is Shimada MKI.  When multiple nodules present in a single Ganglioneuroblastoma, nodular tumor, the higher MKI value is reported.</description><type>encoded value</type><logical_min>1</logical_min><logical_max>9</logical_max><value code="1">Low (&lt;2% or &lt;100/5,000 cells)</value><value code="2">Intermediate (2-4% or 100-&lt;200/5,000 cells)</value><value code="3">High (&gt;4% or &gt;200/5,000 cells)</value><value code="9">Unknown</value></variable><variable id="phv00167629.v1"><name>diag</name><description>Diagnostic Category (Revised INPC).  If INPC diagnostic category is missing, then this is Shimada diagnostic category.</description><type>encoded value</type><logical_min>1</logical_min><logical_max>9</logical_max><value code="1">Neuroblastoma (Schwannian stroma-poor)</value><value code="2">Ganglioneuroblastoma, intermixed (Schwannian stroma-rich)</value><value code="3">Ganglioneuroma (Schwannian stroma-dominant), maturing subtype OR Ganglioneuroblastoma, well differentiated (Schwannian stroma-rich)</value><value code="4">Ganglioneuroblastoma, nodular (composite)</value><value code="9">Unknown</value></variable><variable id="phv00167630.v1"><name>icdo</name><description>ICD-O Topography Code (International Classification of Disease Code)</description><type>string</type></variable><variable id="phv00167631.v1"><name>snomed</name><description>Older Topography Code (Systemized Nomenclature of Medicine-Clinical Terms)</description><type>string</type></variable><variable id="phv00167632.v1"><name>icdo_snomed_description</name><description>Either the ICDO code, or the SNOMED code (if ICDO=999 or Unknown) or a Hard-coded value if both codes unknown but information available</description><type>string</type></variable><variable id="phv00167633.v1"><name>efscens</name><description>Events are described as the first occurrence of relapse, progressive disease, secondary malignancy, or death.</description><type>encoded value</type><logical_min>0</logical_min><logical_max>1</logical_max><value code="0">No event</value><value code="1">Event</value></variable><variable id="phv00167634.v1"><name>scens</name><description>Events are described as the first occurrence of relapse, progressive disease, secondary malignancy, or death.</description><type>encoded value</type><logical_min>0</logical_min><logical_max>1</logical_max><value code="0">Alive</value><value code="1">Dead</value></variable><variable id="phv00167635.v1"><name>efstime</name><description>Number of days from diagnosis until the event, or until last contact if no event</description><type>integer</type><unit>Days</unit><logical_min>1</logical_min><logical_max>5562</logical_max></variable><variable id="phv00167636.v1"><name>stime</name><description>Number of days from diagnosis until death, or until last contact if alive</description><type>integer</type><unit>Days</unit><logical_min>1</logical_min><logical_max>5562</logical_max></variable><variable id="phv00167637.v1"><name>COG Risk Group</name><description>COG risk stratification criteria at the time the patient enrolled</description><type>integer</type><logical_min>1</logical_min><logical_max>3</logical_max><value code="1">Low risk</value><value code="2">Intermediate risk</value><value code="3">High risk, per COG risk stratification criteria at the time the patient enrolled</value></variable><variable id="phv00167638.v1"><name>Protocol(s)</name><description>COG Protocol number on which the patient was enrolled [901=Trial of mouse monoclonal Anti-GD-2 antibody 14.G2A plus IL-2 with or without GM-CSF in children with refractory NBL or melanoma; 911=I-131-MIBG for therapy of advanced neuroblastoma; 914=A dose escalation study of cisplatin, doxorubicin, VP-16, and ifosfamide followed by GM-CSF in advanced NBL and peripheral neuroepithelioma; 925=Study of topotecan; 935=Study of ch14.18 with GM-CSF in children with NBL and other GD2 positive malignancies immediately post ABMT or PBSC; 937=Phase I trial of ZD1694, an inhibitor of thymidylate synthase, in pediatric patients with advanced neoplastic disease; 9709=A phase I study of fenretinide in children with high risk solid tumors; 321P2=New intensive chemotherapy for CCG stage II (with N-myc amplification), stage III and stage IV neuroblastoma; 321P3=Treatment of poor prognosis neuroblastoma before disease progression with intensive multimodal therapy and BMT; 323P=Cyclic combination chemotherapy for newly diagnosed stage III neuroblastoma age 2 and older and stage IV Nneuroblastoma all ages; 3881=Biology and therapy of good, intermediate, and selected poor prognosis neuroblastoma; 3891=Conventional dose chemoradiotherapy vs ablative chemoradiotherapy with autologous BMT for high-risk neuroblastoma; 3951=Phase I pilot study of multiple cycles of high dose chemotherapy with peripheral blood stem cell infusions in advanced stage neuroblastoma.; 4941=National Wilms tumor study V - therapeutic trial &amp;amp; biology study; 8605=Study of the combination of ifosfamide, mesna, and VP-16 in children and young adults with recurrent sarcomas, PNET and other tumors; 8742=Phase III portion of 8741 for neuroblastoma; 9047=Neuroblastoma biology protocol; 9082=Protocol for the development of intervention strategies to reduce the time between symptom onset and diagnosis of childhood cancer -a pediatric oncology group cancer control study; 9140=Therapy for patients with recurrent or refractory neuroblastoma - a phase II study; 9262=A Phase II study of taxol in children with recurrent/refractory soft-tissue sarcoma, rhabdomyosarcoma, osteosarcoma, Ewing&amp;#39;s sarcoma, neuroblastoma, germ cell tumors, Wilms&amp;#39; tumor, hepatoblastoma, and hepatocellular carcinoma, a POG study; 9280=Neuroblastoma epidemiology protocol - A Non-Therapeutic Study - A Joint Project of: The University of North Carolina, The Pediatric Oncology Group and The Children&amp;#39;s Cancer Study Group; 9340=Treatment of patients &amp;gt;365 days at diagnosis with stage IV NBL: Upfront Phase II Window - A Phase II Study; 9341=Treatment of patients &amp;gt;365 days at diagnosis with stage IV and stage IIB/III (N-myc) NBL - a phase III study; 9342=Neuroblastoma #5, bone marrow transplant - a phase III study; 9343=Interleukin-6 in children receiving autologous bone marrow transplantation for advanced neuroblastoma - a pediatric oncology group phase I trial; 9361=Topotecan in pediatric patients with recurrent or progressive solid tumors - a pediatric oncology group phase II study; 9375=Topotecan plus cyclophosphamide in children with solid tumors - a pediatric oncology group phase I trial; 9464=Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors - a pediatric oncology group phase II study; 9640=Treatment of patients with high risk neuroblastoma (a feasibility pilot) using two cycles of marrow ablative chemotherapy followed by rescue With peripheral blood stem cells (PBSC), radiation therapy; A3973=A randomized study of purged vs. unpurged PBSC transplant following dose intensive induction therapy for high risk NBL; AADM01P1=Protocol for registration and consent to the childhood cancer research network: a limited institution pilot; AAML00P2=A dose finding study of the safety of gemtuzumab ozogamicin combined with conventional chemotherapy for patients with relapsed or refractory acute myeloid leukemia; ACCL0331=A Randomized double blind placebo controlled clinical trial to assess the efficacy of traumeel&amp;#174; S (IND # 66649) for the prevention and treatment of mucositis in children undergoing hematopoietic stem cell transplantation; ACCRN07=Protocol for the enrollment on the official COG registry, The Childhood Cancer Research Network (CCRN); ADVL0018=Phase I study of hu14.18-IL2 fusion protein in patients with refractory neuroblastoma and other refractory GD2 expressing tumors; ADVL0212=A Phase I study of depsipeptide (NSC#630176, IND# 51810)  in pediatric patients with refractory solid tumors and leukemias; ADVL0214=A phase I study of single agent OSI-774 (Tarceva) (NSC # 718781, IND #63383) followed by OSI-774 with temozolomide for patients with selected recurrent/refractory solid tumors, including brain tumors; ADVL0215=A phase I study of decitabine in combination with doxorubicin and cyclophosphamide in the treatment of relapsed or refractory solid tumors; ADVL0421=A phase II study of oxaliplatin in children with recurrent solid tumors; ADVL0524=Phase II trial of ixabepilone (BMS-247550), an epothilone B analog, in children and young adults with refractory solid tumors; ADVL0525=A phase II study of pemetrexed in children with recurrent malignancies; ADVL06B1=A pharmacokinetic-pharmacodynamic-pharmacogenetic study of actinomycin-D and vincristine in children with cancer; ADVL0714=A phase I study of VEGF trap (NSC# 724770, IND# 100137) in children with refractory solid tumors; ALTE03N1=Key adverse events after childhood cancer; ALTE05N1=Umbrella long-term follow-up protocol; ANBL0032=Phase III randomized study of chimeric antibody 14.18 (Ch14.18) in high risk neuroblastoma following myeloablative therapy and autologous stem cell rescue; ANBL00B1=Neuroblastoma biology studies; ANBL00P1=A pilot study of tandem high dose chemotherapy with stem cell rescue following induction therapy in children with high risk neuroblastoma; ANBL02P1=A pilot induction regimen incorporating dose-intensive topotecan and cyclophosphamide for treatment of newly diagnosed high risk neuroblastoma; ANBL0321=Phase II study of fenretinide in pediatric patients with resistant or recurrent neuroblastoma; ANBL0322=A phase II study of hu14.18-IL2 (BB-IND-9728) in children with  recurrent or refractory neuroblastoma; ANBL0532=Phase III randomized trial of single vs. tandem myeloablative as consolidation therapy for high-risk neuroblastoma; ANBL0621=A phase II study of ABT-751, an orally bioavailable tubulin binding agent, in children with relapsed or refractory neuroblastoma; B003=Diagnostic &amp;amp; prognostic studies in NBL; B903=Childhood cancer genetics; B947=Protocol for collection of biology specimens for research studies; B954=Opsoclonus-myoclonus-ataxia syndrome, neuroblastoma and the presence of anti-neuronal antibodies; B973=Laboratory-clinical studies of neuroblastoma; E04=Self-administered epidemiology questionnaire; E18=A case-control study of risk factors for neuroblastoma; I03=Neuroblastoma, diagnostic/prognostic; N891=Parents&amp;#39; perceptions of randomization; P9462=Randomized treatment of recurrent neuroblastoma with topotecan regimens following desferrioxamine (POG only) in an investigational window; P9641=Primary surgical therapy for biologically defined low-risk neuroblastoma; P9761=A phase II trial of irinotecan in children with refractory solid tumors; P9963=A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors; R9702=Prognostic implications of MIBG uptake in patients with neuroblastoma previously treated on CCG-3891; S31=Right atrial catheter study; S921=Comparison of urokinase vs heparin in preventing Infection in central venous devices in children with malignancies]</description><type>string</type><value code="901">Trial of mouse monoclonal Anti-GD-2 antibody 14.G2A plus IL-2 with or without GM-CSF in children with refractory NBL or melanoma</value><value code="911">I-131-MIBG for therapy of advanced neuroblastoma</value><value code="914">A dose escalation study of cisplatin, doxorubicin, VP-16, and ifosfamide followed by GM-CSF in advanced NBL and peripheral neuroepithelioma</value><value code="925">Study of topotecan</value><value code="935">Study of ch14.18 with GM-CSF in children with NBL and other GD2 positive malignancies immediately post ABMT or PBSC</value><value code="937">Phase I trial of ZD1694, an inhibitor of thymidylate synthase, in pediatric patients with advanced neoplastic disease</value><value code="9709">A phase I study of fenretinide in children with high risk solid tumors</value><value code="321P2">New intensive chemotherapy for CCG stage II (with N-myc amplification), stage III and stage IV neuroblastoma</value><value code="321P3">Treatment of poor prognosis neuroblastoma before disease progression with intensive multimodal therapy and BMT</value><value code="323P">Cyclic combination chemotherapy for newly diagnosed stage III neuroblastoma age 2 and older and stage IV Nneuroblastoma all ages</value><value code="3881">Biology and therapy of good, intermediate, and selected poor prognosis neuroblastoma</value><value code="3891">Conventional dose chemoradiotherapy vs ablative chemoradiotherapy with autologous BMT for high-risk neuroblastoma</value><value code="3951">Phase I pilot study of multiple cycles of high dose chemotherapy with peripheral blood stem cell infusions in advanced stage neuroblastoma.</value><value code="4941">National Wilms tumor study V - therapeutic trial &amp; biology study</value><value code="8605">Study of the combination of ifosfamide, mesna, and VP-16 in children and young adults with recurrent sarcomas, PNET and other tumors</value><value code="8742">Phase III portion of 8741 for neuroblastoma</value><value code="9047">Neuroblastoma biology protocol</value><value code="9082">Protocol for the development of intervention strategies to reduce the time between symptom onset and diagnosis of childhood cancer -a pediatric oncology group cancer control study</value><value code="9140">Therapy for patients with recurrent or refractory neuroblastoma - a phase II study</value><value code="9262">A Phase II study of taxol in children with recurrent/refractory soft-tissue sarcoma, rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma, neuroblastoma, germ cell tumors, Wilms' tumor, hepatoblastoma, and hepatocellular carcinoma, a POG study</value><value code="9280">Neuroblastoma epidemiology protocol - A Non-Therapeutic Study - A Joint Project of: The University of North Carolina, The Pediatric Oncology Group and The Children's Cancer Study Group</value><value code="9340">Treatment of patients &gt;365 days at diagnosis with stage IV NBL: Upfront Phase II Window - A Phase II Study</value><value code="9341">Treatment of patients &gt;365 days at diagnosis with stage IV and stage IIB/III (N-myc) NBL - a phase III study</value><value code="9342">Neuroblastoma #5, bone marrow transplant - a phase III study</value><value code="9343">Interleukin-6 in children receiving autologous bone marrow transplantation for advanced neuroblastoma - a pediatric oncology group phase I trial</value><value code="9361">Topotecan in pediatric patients with recurrent or progressive solid tumors - a pediatric oncology group phase II study</value><value code="9375">Topotecan plus cyclophosphamide in children with solid tumors - a pediatric oncology group phase I trial</value><value code="9464">Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors - a pediatric oncology group phase II study</value><value code="9640">Treatment of patients with high risk neuroblastoma (a feasibility pilot) using two cycles of marrow ablative chemotherapy followed by rescue With peripheral blood stem cells (PBSC), radiation therapy</value><value code="A3973">A randomized study of purged vs. unpurged PBSC transplant following dose intensive induction therapy for high risk NBL</value><value code="AADM01P1">Protocol for registration and consent to the childhood cancer research network: a limited institution pilot</value><value code="AAML00P2">A dose finding study of the safety of gemtuzumab ozogamicin combined with conventional chemotherapy for patients with relapsed or refractory acute myeloid leukemia</value><value code="ACCL0331">A Randomized double blind placebo controlled clinical trial to assess the efficacy of traumeel® S (IND # 66649) for the prevention and treatment of mucositis in children undergoing hematopoietic stem cell transplantation</value><value code="ACCRN07">Protocol for the enrollment on the official COG registry, The Childhood Cancer Research Network (CCRN)</value><value code="ADVL0018">Phase I study of hu14.18-IL2 fusion protein in patients with refractory neuroblastoma and other refractory GD2 expressing tumors</value><value code="ADVL0212">A Phase I study of depsipeptide (NSC#630176, IND# 51810)  in pediatric patients with refractory solid tumors and leukemias</value><value code="ADVL0214">A phase I study of single agent OSI-774 (Tarceva) (NSC # 718781, IND #63383) followed by OSI-774 with temozolomide for patients with selected recurrent/refractory solid tumors, including brain tumors</value><value code="ADVL0215">A phase I study of decitabine in combination with doxorubicin and cyclophosphamide in the treatment of relapsed or refractory solid tumors</value><value code="ADVL0421">A phase II study of oxaliplatin in children with recurrent solid tumors</value><value code="ADVL0524">Phase II trial of ixabepilone (BMS-247550), an epothilone B analog, in children and young adults with refractory solid tumors</value><value code="ADVL0525">A phase II study of pemetrexed in children with recurrent malignancies</value><value code="ADVL06B1">A pharmacokinetic-pharmacodynamic-pharmacogenetic study of actinomycin-D and vincristine in children with cancer</value><value code="ADVL0714">A phase I study of VEGF trap (NSC# 724770, IND# 100137) in children with refractory solid tumors</value><value code="ALTE03N1">Key adverse events after childhood cancer</value><value code="ALTE05N1">Umbrella long-term follow-up protocol</value><value code="ANBL0032">Phase III randomized study of chimeric antibody 14.18 (Ch14.18) in high risk neuroblastoma following myeloablative therapy and autologous stem cell rescue</value><value code="ANBL00B1">Neuroblastoma biology studies</value><value code="ANBL00P1">A pilot study of tandem high dose chemotherapy with stem cell rescue following induction therapy in children with high risk neuroblastoma</value><value code="ANBL02P1">A pilot induction regimen incorporating dose-intensive topotecan and cyclophosphamide for treatment of newly diagnosed high risk neuroblastoma</value><value code="ANBL0321">Phase II study of fenretinide in pediatric patients with resistant or recurrent neuroblastoma</value><value code="ANBL0322">A phase II study of hu14.18-IL2 (BB-IND-9728) in children with  recurrent or refractory neuroblastoma</value><value code="ANBL0532">Phase III randomized trial of single vs. tandem myeloablative as consolidation therapy for high-risk neuroblastoma</value><value code="ANBL0621">A phase II study of ABT-751, an orally bioavailable tubulin binding agent, in children with relapsed or refractory neuroblastoma</value><value code="B003">Diagnostic &amp; prognostic studies in NBL</value><value code="B903">Childhood cancer genetics</value><value code="B947">Protocol for collection of biology specimens for research studies</value><value code="B954">Opsoclonus-myoclonus-ataxia syndrome, neuroblastoma and the presence of anti-neuronal antibodies</value><value code="B973">Laboratory-clinical studies of neuroblastoma</value><value code="E04">Self-administered epidemiology questionnaire</value><value code="E18">A case-control study of risk factors for neuroblastoma</value><value code="I03">Neuroblastoma, diagnostic/prognostic</value><value code="N891">Parents' perceptions of randomization</value><value code="P9462">Randomized treatment of recurrent neuroblastoma with topotecan regimens following desferrioxamine (POG only) in an investigational window</value><value code="P9641">Primary surgical therapy for biologically defined low-risk neuroblastoma</value><value code="P9761">A phase II trial of irinotecan in children with refractory solid tumors</value><value code="P9963">A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors</value><value code="R9702">Prognostic implications of MIBG uptake in patients with neuroblastoma previously treated on CCG-3891</value><value code="S31">Right atrial catheter study</value><value code="S921">Comparison of urokinase vs heparin in preventing Infection in central venous devices in children with malignancies</value></variable><variable id="phv00167639.v1"><name>percent_tumor</name><description>Proportion of specimen (tumor vs non-tumor), as estimated on specimen quality control review by the Biopathology Center in Columbus</description><type>integer</type><unit>%</unit><logical_min>0</logical_min><logical_max>0.98</logical_max></variable><variable id="phv00167640.v1"><name>percent_necrosis</name><description>Proportion of tumor (necrotic vs viable), as estimated on specimen quality control review by the Biopathology Center in Columbus</description><type>integer</type><unit>%</unit><logical_min>0</logical_min><logical_max>1</logical_max></variable></data_table>
